1. Home
  2. BFS vs ANNX Comparison

BFS vs ANNX Comparison

Compare BFS & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BFS

Saul Centers Inc.

HOLD

Current Price

$33.54

Market Cap

770.9M

Sector

Real Estate

ML Signal

HOLD

Logo Annexon Inc.

ANNX

Annexon Inc.

HOLD

Current Price

$5.47

Market Cap

730.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BFS
ANNX
Founded
1993
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
770.9M
730.4M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
BFS
ANNX
Price
$33.54
$5.47
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$16.50
AVG Volume (30 Days)
54.7K
2.2M
Earning Date
05-07-2026
03-05-2026
Dividend Yield
7.11%
N/A
EPS Growth
N/A
42.94
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$6.07
N/A
Revenue Next Year
$7.05
N/A
P/E Ratio
$30.48
N/A
Revenue Growth
N/A
N/A
52 Week Low
$29.16
$1.29
52 Week High
$36.51
$7.18

Technical Indicators

Market Signals
Indicator
BFS
ANNX
Relative Strength Index (RSI) 43.60 49.49
Support Level $32.53 $4.77
Resistance Level $35.18 $5.61
Average True Range (ATR) 0.88 0.35
MACD -0.19 0.01
Stochastic Oscillator 32.43 33.89

Price Performance

Historical Comparison
BFS
ANNX

About BFS Saul Centers Inc.

Saul Centers Inc is a self-managed real estate investment trust which invests in, operates and develops retail and commercial properties. The company's portfolio includes community and neighbourhood shopping centres, office properties, and mixed-use properties. Properties are located in the Washington, D.C. and Batlimore metropolitan areas. Saul Centers operates through two business segments: shopping centers, which contribute the maximum portion of total revenue; and mixed-use properties. Maximum tenants include grocery stores, discount department stores, and drug stores.

About ANNX Annexon Inc.

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.

Share on Social Networks: